ANNALS OF HEMATOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2157610, encodeId=45f2215e610ff, content=审稿速度:1.0 偏重的研究方向：hematology 经验分享：under review 状态一般持续多久呀？临床型的文章更容易中吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Thu Sep 14 00:23:58 CST 2023, time=2023-09-14, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2128572, encodeId=f10c21285e230, content=大修了两周了还没信…555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Thu Apr 27 02:16:05 CST 2023, time=2023-04-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126114, encodeId=42b7212611423, content=偏重的研究方向：白血病 经验分享：最近给这个杂志审过几篇稿子，一般是如果超过两周不给审的话就停止邀请，换审稿人了，接受审稿之后每周都会发来提醒邮件的。大修的稿子会返回给审稿人看的。感觉还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Sat Apr 15 19:33:15 CST 2023, time=2023-04-15, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120443, encodeId=ffa8212044308, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65c8353596, createdName=ms9000000180277427, createdTime=Sun Mar 19 17:17:39 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965492, encodeId=af3c96549287, content=请问版面费多少？接收case report吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd4e2482810, createdName=12460bffm61暂无昵称, createdTime=Fri May 14 11:13:26 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977647, encodeId=287b9e7647f7, content=请问接受个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ca9f5408920, createdName=ms1000000940702777, createdTime=Mon Jun 28 17:54:44 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975847, encodeId=08639e58478e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液病 经验分享：一个月给了意见，给了3个月，修回接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a1f5188251, createdName=1470fb34m70(暂无昵称), createdTime=Tue Jun 22 16:57:26 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580115, encodeId=101458011551, content=一直都是with editor，不知道送外审会是什么状态159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, beContent=159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/07/daf9b2a0c54c44f56adacf00fe8c4244.jpg, createdBy=356a5091985, createdName=13045d5bb3m, createdTime=Tue Nov 19 00:00:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187968, encodeId=7c5b118e9686f, content=偏重的研究方向：白血病 经验分享：2022年1月23投，现在还是submit to Journal，求问这个状态啥时候才会提交给编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=ms4000000531946229, createdTime=Tue Jan 25 10:50:34 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086715, encodeId=8d891086e153e, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:47 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-09-14 清清欢来自江西省

审稿速度:1.0
偏重的研究方向：hematology
经验分享：under review 状态一般持续多久呀？临床型的文章更容易中吗？

59 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157610, encodeId=45f2215e610ff, content=审稿速度:1.0 偏重的研究方向：hematology 经验分享：under review 状态一般持续多久呀？临床型的文章更容易中吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Thu Sep 14 00:23:58 CST 2023, time=2023-09-14, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2128572, encodeId=f10c21285e230, content=大修了两周了还没信…555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Thu Apr 27 02:16:05 CST 2023, time=2023-04-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126114, encodeId=42b7212611423, content=偏重的研究方向：白血病 经验分享：最近给这个杂志审过几篇稿子，一般是如果超过两周不给审的话就停止邀请，换审稿人了，接受审稿之后每周都会发来提醒邮件的。大修的稿子会返回给审稿人看的。感觉还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Sat Apr 15 19:33:15 CST 2023, time=2023-04-15, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120443, encodeId=ffa8212044308, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65c8353596, createdName=ms9000000180277427, createdTime=Sun Mar 19 17:17:39 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965492, encodeId=af3c96549287, content=请问版面费多少？接收case report吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd4e2482810, createdName=12460bffm61暂无昵称, createdTime=Fri May 14 11:13:26 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977647, encodeId=287b9e7647f7, content=请问接受个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ca9f5408920, createdName=ms1000000940702777, createdTime=Mon Jun 28 17:54:44 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975847, encodeId=08639e58478e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液病 经验分享：一个月给了意见，给了3个月，修回接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a1f5188251, createdName=1470fb34m70(暂无昵称), createdTime=Tue Jun 22 16:57:26 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580115, encodeId=101458011551, content=一直都是with editor，不知道送外审会是什么状态159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, beContent=159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/07/daf9b2a0c54c44f56adacf00fe8c4244.jpg, createdBy=356a5091985, createdName=13045d5bb3m, createdTime=Tue Nov 19 00:00:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187968, encodeId=7c5b118e9686f, content=偏重的研究方向：白血病 经验分享：2022年1月23投，现在还是submit to Journal，求问这个状态啥时候才会提交给编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=ms4000000531946229, createdTime=Tue Jan 25 10:50:34 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086715, encodeId=8d891086e153e, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:47 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-04-27 ms7000000764732971 来自北京

大修了两周了还没信…555

57 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157610, encodeId=45f2215e610ff, content=审稿速度:1.0 偏重的研究方向：hematology 经验分享：under review 状态一般持续多久呀？临床型的文章更容易中吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Thu Sep 14 00:23:58 CST 2023, time=2023-09-14, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2128572, encodeId=f10c21285e230, content=大修了两周了还没信…555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Thu Apr 27 02:16:05 CST 2023, time=2023-04-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126114, encodeId=42b7212611423, content=偏重的研究方向：白血病 经验分享：最近给这个杂志审过几篇稿子，一般是如果超过两周不给审的话就停止邀请，换审稿人了，接受审稿之后每周都会发来提醒邮件的。大修的稿子会返回给审稿人看的。感觉还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Sat Apr 15 19:33:15 CST 2023, time=2023-04-15, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120443, encodeId=ffa8212044308, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65c8353596, createdName=ms9000000180277427, createdTime=Sun Mar 19 17:17:39 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965492, encodeId=af3c96549287, content=请问版面费多少？接收case report吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd4e2482810, createdName=12460bffm61暂无昵称, createdTime=Fri May 14 11:13:26 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977647, encodeId=287b9e7647f7, content=请问接受个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ca9f5408920, createdName=ms1000000940702777, createdTime=Mon Jun 28 17:54:44 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975847, encodeId=08639e58478e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液病 经验分享：一个月给了意见，给了3个月，修回接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a1f5188251, createdName=1470fb34m70(暂无昵称), createdTime=Tue Jun 22 16:57:26 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580115, encodeId=101458011551, content=一直都是with editor，不知道送外审会是什么状态159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, beContent=159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/07/daf9b2a0c54c44f56adacf00fe8c4244.jpg, createdBy=356a5091985, createdName=13045d5bb3m, createdTime=Tue Nov 19 00:00:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187968, encodeId=7c5b118e9686f, content=偏重的研究方向：白血病 经验分享：2022年1月23投，现在还是submit to Journal，求问这个状态啥时候才会提交给编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=ms4000000531946229, createdTime=Tue Jan 25 10:50:34 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086715, encodeId=8d891086e153e, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:47 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-04-15 suguoqing.my265 来自吉林省

偏重的研究方向：白血病
经验分享：最近给这个杂志审过几篇稿子，一般是如果超过两周不给审的话就停止邀请，换审稿人了，接受审稿之后每周都会发来提醒邮件的。大修的稿子会返回给审稿人看的。感觉还行。

57 0

[GetPortalCommentsPageByObjectIdResponse(id=2157610, encodeId=45f2215e610ff, content=审稿速度:1.0 偏重的研究方向：hematology 经验分享：under review 状态一般持续多久呀？临床型的文章更容易中吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Thu Sep 14 00:23:58 CST 2023, time=2023-09-14, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2128572, encodeId=f10c21285e230, content=大修了两周了还没信…555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Thu Apr 27 02:16:05 CST 2023, time=2023-04-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126114, encodeId=42b7212611423, content=偏重的研究方向：白血病 经验分享：最近给这个杂志审过几篇稿子，一般是如果超过两周不给审的话就停止邀请，换审稿人了，接受审稿之后每周都会发来提醒邮件的。大修的稿子会返回给审稿人看的。感觉还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Sat Apr 15 19:33:15 CST 2023, time=2023-04-15, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120443, encodeId=ffa8212044308, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65c8353596, createdName=ms9000000180277427, createdTime=Sun Mar 19 17:17:39 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965492, encodeId=af3c96549287, content=请问版面费多少？接收case report吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd4e2482810, createdName=12460bffm61暂无昵称, createdTime=Fri May 14 11:13:26 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977647, encodeId=287b9e7647f7, content=请问接受个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ca9f5408920, createdName=ms1000000940702777, createdTime=Mon Jun 28 17:54:44 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975847, encodeId=08639e58478e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液病 经验分享：一个月给了意见，给了3个月，修回接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a1f5188251, createdName=1470fb34m70(暂无昵称), createdTime=Tue Jun 22 16:57:26 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580115, encodeId=101458011551, content=一直都是with editor，不知道送外审会是什么状态159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, beContent=159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/07/daf9b2a0c54c44f56adacf00fe8c4244.jpg, createdBy=356a5091985, createdName=13045d5bb3m, createdTime=Tue Nov 19 00:00:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187968, encodeId=7c5b118e9686f, content=偏重的研究方向：白血病 经验分享：2022年1月23投，现在还是submit to Journal，求问这个状态啥时候才会提交给编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=ms4000000531946229, createdTime=Tue Jan 25 10:50:34 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086715, encodeId=8d891086e153e, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:47 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-03-19 ms9000000180277427

审稿速度:2.0 | 投稿命中率:50.0
经验分享：。

57 0

[GetPortalCommentsPageByObjectIdResponse(id=2157610, encodeId=45f2215e610ff, content=审稿速度:1.0 偏重的研究方向：hematology 经验分享：under review 状态一般持续多久呀？临床型的文章更容易中吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Thu Sep 14 00:23:58 CST 2023, time=2023-09-14, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2128572, encodeId=f10c21285e230, content=大修了两周了还没信…555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Thu Apr 27 02:16:05 CST 2023, time=2023-04-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126114, encodeId=42b7212611423, content=偏重的研究方向：白血病 经验分享：最近给这个杂志审过几篇稿子，一般是如果超过两周不给审的话就停止邀请，换审稿人了，接受审稿之后每周都会发来提醒邮件的。大修的稿子会返回给审稿人看的。感觉还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Sat Apr 15 19:33:15 CST 2023, time=2023-04-15, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120443, encodeId=ffa8212044308, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65c8353596, createdName=ms9000000180277427, createdTime=Sun Mar 19 17:17:39 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965492, encodeId=af3c96549287, content=请问版面费多少？接收case report吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd4e2482810, createdName=12460bffm61暂无昵称, createdTime=Fri May 14 11:13:26 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977647, encodeId=287b9e7647f7, content=请问接受个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ca9f5408920, createdName=ms1000000940702777, createdTime=Mon Jun 28 17:54:44 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975847, encodeId=08639e58478e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液病 经验分享：一个月给了意见，给了3个月，修回接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a1f5188251, createdName=1470fb34m70(暂无昵称), createdTime=Tue Jun 22 16:57:26 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580115, encodeId=101458011551, content=一直都是with editor，不知道送外审会是什么状态159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, beContent=159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/07/daf9b2a0c54c44f56adacf00fe8c4244.jpg, createdBy=356a5091985, createdName=13045d5bb3m, createdTime=Tue Nov 19 00:00:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187968, encodeId=7c5b118e9686f, content=偏重的研究方向：白血病 经验分享：2022年1月23投，现在还是submit to Journal，求问这个状态啥时候才会提交给编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=ms4000000531946229, createdTime=Tue Jan 25 10:50:34 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086715, encodeId=8d891086e153e, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:47 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-05-14 12460bffm61暂无昵称

请问版面费多少？接收case report吗？

126 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157610, encodeId=45f2215e610ff, content=审稿速度:1.0 偏重的研究方向：hematology 经验分享：under review 状态一般持续多久呀？临床型的文章更容易中吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Thu Sep 14 00:23:58 CST 2023, time=2023-09-14, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2128572, encodeId=f10c21285e230, content=大修了两周了还没信…555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Thu Apr 27 02:16:05 CST 2023, time=2023-04-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126114, encodeId=42b7212611423, content=偏重的研究方向：白血病 经验分享：最近给这个杂志审过几篇稿子，一般是如果超过两周不给审的话就停止邀请，换审稿人了，接受审稿之后每周都会发来提醒邮件的。大修的稿子会返回给审稿人看的。感觉还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Sat Apr 15 19:33:15 CST 2023, time=2023-04-15, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120443, encodeId=ffa8212044308, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65c8353596, createdName=ms9000000180277427, createdTime=Sun Mar 19 17:17:39 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965492, encodeId=af3c96549287, content=请问版面费多少？接收case report吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd4e2482810, createdName=12460bffm61暂无昵称, createdTime=Fri May 14 11:13:26 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977647, encodeId=287b9e7647f7, content=请问接受个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ca9f5408920, createdName=ms1000000940702777, createdTime=Mon Jun 28 17:54:44 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975847, encodeId=08639e58478e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液病 经验分享：一个月给了意见，给了3个月，修回接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a1f5188251, createdName=1470fb34m70(暂无昵称), createdTime=Tue Jun 22 16:57:26 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580115, encodeId=101458011551, content=一直都是with editor，不知道送外审会是什么状态159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, beContent=159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/07/daf9b2a0c54c44f56adacf00fe8c4244.jpg, createdBy=356a5091985, createdName=13045d5bb3m, createdTime=Tue Nov 19 00:00:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187968, encodeId=7c5b118e9686f, content=偏重的研究方向：白血病 经验分享：2022年1月23投，现在还是submit to Journal，求问这个状态啥时候才会提交给编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=ms4000000531946229, createdTime=Tue Jan 25 10:50:34 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086715, encodeId=8d891086e153e, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:47 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-06-28 ms1000000940702777

请问接受个案吗？

219 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157610, encodeId=45f2215e610ff, content=审稿速度:1.0 偏重的研究方向：hematology 经验分享：under review 状态一般持续多久呀？临床型的文章更容易中吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Thu Sep 14 00:23:58 CST 2023, time=2023-09-14, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2128572, encodeId=f10c21285e230, content=大修了两周了还没信…555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Thu Apr 27 02:16:05 CST 2023, time=2023-04-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126114, encodeId=42b7212611423, content=偏重的研究方向：白血病 经验分享：最近给这个杂志审过几篇稿子，一般是如果超过两周不给审的话就停止邀请，换审稿人了，接受审稿之后每周都会发来提醒邮件的。大修的稿子会返回给审稿人看的。感觉还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Sat Apr 15 19:33:15 CST 2023, time=2023-04-15, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120443, encodeId=ffa8212044308, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65c8353596, createdName=ms9000000180277427, createdTime=Sun Mar 19 17:17:39 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965492, encodeId=af3c96549287, content=请问版面费多少？接收case report吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd4e2482810, createdName=12460bffm61暂无昵称, createdTime=Fri May 14 11:13:26 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977647, encodeId=287b9e7647f7, content=请问接受个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ca9f5408920, createdName=ms1000000940702777, createdTime=Mon Jun 28 17:54:44 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975847, encodeId=08639e58478e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液病 经验分享：一个月给了意见，给了3个月，修回接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a1f5188251, createdName=1470fb34m70(暂无昵称), createdTime=Tue Jun 22 16:57:26 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580115, encodeId=101458011551, content=一直都是with editor，不知道送外审会是什么状态159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, beContent=159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/07/daf9b2a0c54c44f56adacf00fe8c4244.jpg, createdBy=356a5091985, createdName=13045d5bb3m, createdTime=Tue Nov 19 00:00:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187968, encodeId=7c5b118e9686f, content=偏重的研究方向：白血病 经验分享：2022年1月23投，现在还是submit to Journal，求问这个状态啥时候才会提交给编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=ms4000000531946229, createdTime=Tue Jan 25 10:50:34 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086715, encodeId=8d891086e153e, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:47 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-06-22 1470fb34m70(暂无昵称)

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：血液病
经验分享：一个月给了意见，给了3个月，修回接受

199 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157610, encodeId=45f2215e610ff, content=审稿速度:1.0 偏重的研究方向：hematology 经验分享：under review 状态一般持续多久呀？临床型的文章更容易中吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Thu Sep 14 00:23:58 CST 2023, time=2023-09-14, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2128572, encodeId=f10c21285e230, content=大修了两周了还没信…555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Thu Apr 27 02:16:05 CST 2023, time=2023-04-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126114, encodeId=42b7212611423, content=偏重的研究方向：白血病 经验分享：最近给这个杂志审过几篇稿子，一般是如果超过两周不给审的话就停止邀请，换审稿人了，接受审稿之后每周都会发来提醒邮件的。大修的稿子会返回给审稿人看的。感觉还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Sat Apr 15 19:33:15 CST 2023, time=2023-04-15, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120443, encodeId=ffa8212044308, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65c8353596, createdName=ms9000000180277427, createdTime=Sun Mar 19 17:17:39 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965492, encodeId=af3c96549287, content=请问版面费多少？接收case report吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd4e2482810, createdName=12460bffm61暂无昵称, createdTime=Fri May 14 11:13:26 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977647, encodeId=287b9e7647f7, content=请问接受个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ca9f5408920, createdName=ms1000000940702777, createdTime=Mon Jun 28 17:54:44 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975847, encodeId=08639e58478e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液病 经验分享：一个月给了意见，给了3个月，修回接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a1f5188251, createdName=1470fb34m70(暂无昵称), createdTime=Tue Jun 22 16:57:26 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580115, encodeId=101458011551, content=一直都是with editor，不知道送外审会是什么状态159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, beContent=159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/07/daf9b2a0c54c44f56adacf00fe8c4244.jpg, createdBy=356a5091985, createdName=13045d5bb3m, createdTime=Tue Nov 19 00:00:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187968, encodeId=7c5b118e9686f, content=偏重的研究方向：白血病 经验分享：2022年1月23投，现在还是submit to Journal，求问这个状态啥时候才会提交给编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=ms4000000531946229, createdTime=Tue Jan 25 10:50:34 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086715, encodeId=8d891086e153e, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:47 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2019-11-19 13045d5bb3m

一直都是with editor，不知道送外审会是什么状态159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表:
你的送外审了吗

159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗

31 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157610, encodeId=45f2215e610ff, content=审稿速度:1.0 偏重的研究方向：hematology 经验分享：under review 状态一般持续多久呀？临床型的文章更容易中吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Thu Sep 14 00:23:58 CST 2023, time=2023-09-14, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2128572, encodeId=f10c21285e230, content=大修了两周了还没信…555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Thu Apr 27 02:16:05 CST 2023, time=2023-04-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126114, encodeId=42b7212611423, content=偏重的研究方向：白血病 经验分享：最近给这个杂志审过几篇稿子，一般是如果超过两周不给审的话就停止邀请，换审稿人了，接受审稿之后每周都会发来提醒邮件的。大修的稿子会返回给审稿人看的。感觉还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Sat Apr 15 19:33:15 CST 2023, time=2023-04-15, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120443, encodeId=ffa8212044308, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65c8353596, createdName=ms9000000180277427, createdTime=Sun Mar 19 17:17:39 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965492, encodeId=af3c96549287, content=请问版面费多少？接收case report吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd4e2482810, createdName=12460bffm61暂无昵称, createdTime=Fri May 14 11:13:26 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977647, encodeId=287b9e7647f7, content=请问接受个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ca9f5408920, createdName=ms1000000940702777, createdTime=Mon Jun 28 17:54:44 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975847, encodeId=08639e58478e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液病 经验分享：一个月给了意见，给了3个月，修回接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a1f5188251, createdName=1470fb34m70(暂无昵称), createdTime=Tue Jun 22 16:57:26 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580115, encodeId=101458011551, content=一直都是with editor，不知道送外审会是什么状态159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, beContent=159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/07/daf9b2a0c54c44f56adacf00fe8c4244.jpg, createdBy=356a5091985, createdName=13045d5bb3m, createdTime=Tue Nov 19 00:00:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187968, encodeId=7c5b118e9686f, content=偏重的研究方向：白血病 经验分享：2022年1月23投，现在还是submit to Journal，求问这个状态啥时候才会提交给编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=ms4000000531946229, createdTime=Tue Jan 25 10:50:34 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086715, encodeId=8d891086e153e, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:47 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2022-01-25 ms4000000531946229

偏重的研究方向：白血病
经验分享：2022年1月23投，现在还是submit to Journal，求问这个状态啥时候才会提交给编辑

159 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2157610, encodeId=45f2215e610ff, content=审稿速度:1.0 偏重的研究方向：hematology 经验分享：under review 状态一般持续多久呀？临床型的文章更容易中吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Thu Sep 14 00:23:58 CST 2023, time=2023-09-14, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2128572, encodeId=f10c21285e230, content=大修了两周了还没信…555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Thu Apr 27 02:16:05 CST 2023, time=2023-04-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2126114, encodeId=42b7212611423, content=偏重的研究方向：白血病 经验分享：最近给这个杂志审过几篇稿子，一般是如果超过两周不给审的话就停止邀请，换审稿人了，接受审稿之后每周都会发来提醒邮件的。大修的稿子会返回给审稿人看的。感觉还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Sat Apr 15 19:33:15 CST 2023, time=2023-04-15, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120443, encodeId=ffa8212044308, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65c8353596, createdName=ms9000000180277427, createdTime=Sun Mar 19 17:17:39 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965492, encodeId=af3c96549287, content=请问版面费多少？接收case report吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dd4e2482810, createdName=12460bffm61暂无昵称, createdTime=Fri May 14 11:13:26 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977647, encodeId=287b9e7647f7, content=请问接受个案吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=219, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ca9f5408920, createdName=ms1000000940702777, createdTime=Mon Jun 28 17:54:44 CST 2021, time=2021-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975847, encodeId=08639e58478e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液病 经验分享：一个月给了意见，给了3个月，修回接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a1f5188251, createdName=1470fb34m70(暂无昵称), createdTime=Tue Jun 22 16:57:26 CST 2021, time=2021-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580115, encodeId=101458011551, content=一直都是with editor，不知道送外审会是什么状态159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, beContent=159X8RJ0511(暂无昵称) 2019-11-19 00:00:00 发表: 你的送外审了吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/07/daf9b2a0c54c44f56adacf00fe8c4244.jpg, createdBy=356a5091985, createdName=13045d5bb3m, createdTime=Tue Nov 19 00:00:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187968, encodeId=7c5b118e9686f, content=偏重的研究方向：白血病 经验分享：2022年1月23投，现在还是submit to Journal，求问这个状态啥时候才会提交给编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd785646397, createdName=ms4000000531946229, createdTime=Tue Jan 25 10:50:34 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086715, encodeId=8d891086e153e, content=选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:47 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-12-28 学医的彭于晏

选刊时需要从高到低设置期刊梯度吗？一般设置几个梯度？

177 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务